Try our beta test site

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2017 by Tokyo Medical University
Sponsor:
Information provided by (Responsible Party):
Tokyo Medical University
ClinicalTrials.gov Identifier:
NCT03019419
First received: January 10, 2017
Last updated: NA
Last verified: January 2017
History: No changes posted
  Purpose
To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis

Condition Intervention Phase
ALS
Drug: Perampanel
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials

Resource links provided by NLM:


Further study details as provided by Tokyo Medical University:

Primary Outcome Measures:
  • Change in ALS Functional rating scale [ Time Frame: 48 weeks ]

Secondary Outcome Measures:
  • Change in ALS Functional rating scale [ Time Frame: 12, 24, 36, and 48 weeks ]
  • Manual Muscle Test [ Time Frame: 12, 24, 36, and 48 weeks ]
  • Percent-predicted forced vital capacity [ Time Frame: 12, 24, 36, and 48 weeks ]

Estimated Enrollment: 60
Study Start Date: April 2017
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Perampanel 4mg
Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
Drug: Perampanel
Other Name: non-competitive AMAP antagonist
Experimental: Perampanel 8mg
Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
Drug: Perampanel
Other Name: non-competitive AMAP antagonist
Placebo Comparator: Placebo
Once daily placebo for control for 48 weeks
Drug: placebo

Detailed Description:
To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)
  Eligibility

Ages Eligible for Study:   40 Years to 78 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

[Eligibility Criteria for Interim Registration]

  • Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
  • Patients who are male or female aged 40 years to 78 years at the time of obtaining informed consent
  • Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria.
  • The sum of the 3 respiratory items of the ALSFRS-R must total 12 points or more
  • Patients within 2-year elapsed time period from disease onset at the time of obtaining informed consent
  • Patients who can visit study site for out-patient treatment

[Eligibility Criteria for Registration]

Subjects who meet the following criteria in addition to the inclusion criteria for the interim registration

  • The progression on score of ALSFRS-R during 12 weeks of observation period must be between -2 and -5
  • Patients who has not initiated newly introduced riluzole therapy after starting the observation period. Or those who has not received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation
  • Patients who has not initiated newly introduced edaravone therapy after starting the observation period
  • Patients who are judged to be eligible for continuation of the study by the investigators

[Exclusion Criteria]

  • Patients who underwent tracheostomy.
  • Patients who experienced non-invasive positive pressure ventilation.
  • Patients whose percent-predicted forced vital capacity (%FVC) is ≤80%.
  • Patients with progressive bulbar palsy type.
  • Patients with cognitive impairment, severe disease in the renal, cardiovascular, or hematological system.
  • Patients with hepatic disease.
  • Patients with malignant tumor.
  • Pregnant women or women with a possibility of becoming pregnant.
  • Patients who participated in another clinical study within 12 weeks before starting the observation period.
  • Patients who has initiated perampanel therapy in the past or at present.
  • Patients who are judged to be ineligible for study entry by the investigators.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03019419

Contacts
Contact: Hitoshi Aizawa, M.D.,Ph.D haizawa@tokyo-med.ac.jp

Sponsors and Collaborators
Tokyo Medical University
Investigators
Principal Investigator: Hitoshi Aizawa, M.D.,Ph.D Tokyo Medical University
  More Information

Responsible Party: Tokyo Medical University
ClinicalTrials.gov Identifier: NCT03019419     History of Changes
Other Study ID Numbers: A2016-J000-001
Study First Received: January 10, 2017
Last Updated: January 10, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Tokyo Medical University:
sporadic ALS
perampanel

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases

ClinicalTrials.gov processed this record on March 23, 2017